Hormonal
Incretin-based anti-obesity medications (GLP-1 and GIP/GLP-1 receptor agonists) cause gastrointestinal adverse effects (nausea, diarrhea, constipation) in 65–84% of patients, primarily through delayed gastric emptying and central appetite signaling activation.
If you start a GLP-1 or GIP medication, expect stomach issues like nausea or diarrhea in the first few weeks. This is very common (affecting up to 84% of users). To manage it, start with a low dose and increase slowly. Eat small, low-fat meals, stay hydrated, and avoid spicy or fatty foods. Most symptoms improve as your body adjusts.
Clinical trial data on AOMs indicate that GI AEs are reported in 65–84% of patients treated with liraglutide, semaglutide or tirzepatide... These symptoms are primarily attributed to altered gastric motility and hormone-mediated changes in appetite signaling.
Why this rating
Based on multiple randomized controlled trials (STEP, SURMOUNT programs) and meta-analyses cited.
Source
Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies
Tomasz Witaszek et al. · Biomedicines · 2025
DOI 10.3390/biomedicines13102362
More from this paper
- Tirzepatide (a dual GIP/GLP-1 agonist) is better tolerated regarding GI side effects compared to semaglutide (a GLP-1 agonist), likely due to GIP receptor activation having anti-emetic properties.Good
- Rapid weight loss, whether from very-low-calorie diets or bariatric surgery, significantly increases the risk of gallstone formation (cholelithiasis) due to bile supersaturation and reduced gallbladder motility.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →